Alnylam Notches a Game-Changing RNAi Win
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is researching therapies that can treat genetic diseases by interfering with gene expression. Though Alnylam has yet to validate its approach with a Food and Drug Administration approval for one of its drugs, that could change following the release of positive late-stage trial results for patisiran, a drug that may delay disease progression in patients diagnosed with hereditary forms of amyloidosis with polyneuropathy.
In 1986, Richard Jorgensen of the University of Arizona in Tucson introduced a genetic code (DNA) into petunias to make their color more vivid. Instead, he stumbled upon an important genetic discovery. Instead of the gene's messengers (RNA) creating proteins that enhanced the petunias' color, some petunias lost all their color altogether.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Sanofi S.A. ADR Stock
Our community is currently high on Sanofi S.A. ADR with 4 Buy predictions and 0 Sell predictions.
With a target price of 49 € there is a positive potential of 29.63% for Sanofi S.A. ADR compared to the current price of 37.8 €.
